Hutchmed reports progress in late-stage lung cancer trial
(Alliance News) - Hutchmed China Ltd on Monday said its combination therapy for a specific form of advanced lung cancer significantly delayed disease progression compared to chemotherapy, based on phase III trial data presented at a major oncology conference. Read More